ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DARE vs ALLR // RSI-14 & 200D SMA MOMENTUM

Dare Bioscience Inc. (NASDAQ) VS. Allarity Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DARE 2 — ALLR 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: DARE
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DARE VS. ALLR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DARE ALLR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 71.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 DARE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 42.9 38.9 +4.03 DARE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $13.4M $14.2M -$756.1K ALLR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DARE REV ALLR REV DARE GROSS % ALLR GROSS % DARE FCF ALLR FCF
FY 2025 $1.0M $0 71.3% — -$10.3M -$14.8M
FY 2024 $9.8K $0 98.0% — $4.9M -$17.6M
FY 2023 $2.8M $0 — — -$38.9M -$12.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DARE // BETA —
ALLR // BETA —